VRDN vs. PMD, FTRE, VCYT, CDNA, CSTL, FLGT, CELC, SERA, BDSX, and BNR
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Psychemedics (PMD), Fortrea (FTRE), Veracyte (VCYT), CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Celcuity (CELC), Sera Prognostics (SERA), Biodesix (BDSX), and Burning Rock Biotech (BNR). These companies are all part of the "medical laboratories" industry.
Viridian Therapeutics (NASDAQ:VRDN) and Psychemedics (NASDAQ:PMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends.
Psychemedics received 93 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. Likewise, 74.35% of users gave Psychemedics an outperform vote while only 72.06% of users gave Viridian Therapeutics an outperform vote.
In the previous week, Psychemedics had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 4 mentions for Psychemedics and 3 mentions for Viridian Therapeutics. Psychemedics' average media sentiment score of 1.43 beat Viridian Therapeutics' score of 1.28 indicating that Psychemedics is being referred to more favorably in the news media.
Viridian Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Psychemedics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Viridian Therapeutics presently has a consensus price target of $34.60, suggesting a potential upside of 186.19%. Given Viridian Therapeutics' higher probable upside, equities research analysts plainly believe Viridian Therapeutics is more favorable than Psychemedics.
Psychemedics has a net margin of -20.23% compared to Viridian Therapeutics' net margin of -75,737.85%. Psychemedics' return on equity of -59.21% beat Viridian Therapeutics' return on equity.
32.1% of Psychemedics shares are owned by institutional investors. 0.7% of Viridian Therapeutics shares are owned by insiders. Comparatively, 24.0% of Psychemedics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Psychemedics has higher revenue and earnings than Viridian Therapeutics. Psychemedics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Psychemedics beats Viridian Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
